BOSTON, MA -- (Marketwired) -- 11/08/17 -- Real world evidence is poised to play a growing…
Continue ReadingTag: biotechnology
Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 09/12/17 -- Although the rate at which investigational drugs received marketing…
Continue Reading
Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 07/13/17 -- Although 10 new opioid products with abuse-deterrent formulations (ADF)…
Continue Reading
Accelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 05/09/17 -- Biopharmaceuticals accounted for 35% of all new drug approvals…
Continue Reading
SV Life Sciences Changes Name to SV Health Investors to Better Reflect the Firm–s Longstanding Strategy and Focus
BOSTON, MA -- (Marketwired) -- 04/10/17 -- SV Life Sciences has changed its name to ,…
Continue Reading
Poor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 01/11/17 -- Although physicians and nurses are familiar with, and comfortable…
Continue Reading
ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference
YONKERS, NY -- (Marketwired) -- 12/04/14 -- (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company…
Continue Reading
ContraFect Submits Complete Response to IND Clinical Hold for CF-301
YONKERS, NY -- (Marketwired) -- 12/02/14 -- (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company…
Continue Reading
Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 11/18/14 -- Developing a new prescription medicine that gains marketing approval,…
Continue Reading
ContraFect Corporation Announces Third Quarter 2014 Results
YONKERS, NY -- (Marketwired) -- 11/14/14 -- (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company…
Continue Reading